Hemab Presents Positive HMB-002 Clinical Data In VWD; Unveils HMB-003 For Heavy Menstrual Bleeding

Source and reference

source on Google Add Now Hemab Therapeutics ( COAG ), a clinical-stage biotechnology company, presented new positive clinical data from HMB-002 in Von Willebrand disease (VWD) and announced the HMB-003 program in development for Heavy Menstrual Bleeding at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. Company Profile Hemab Therapeutics develops therapies for blood coagulation disorders. Hemab's development pipeline focused on addressing gaps in the treatment of coagulation disorders includes: - Sutacimig (HMB-001), for the prophylactic treatment of Glanzmann thrombasthenia and...